Skip to main content

Ask your doctor about a switch to Esperoct®.

Experience the Esperoct® difference with less frequent dosing and longer lasting factor.

Man working out outside

This is the prophylaxis offering high factor levels from one dose to the next in adults and adolescents.

Combining FVIII with PEGylation technology, Esperoct® provides high factor levels and longer protection against bleeds.a

factor levels above 3% statistic
factor levels above 3% statistic
factor levels above 5% statistic
factor levels above 5% statistic

aCompared with SHL products.
bTrough level goal is 1% for prophylaxis.
cData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18years) were 2.7 IU/dL.
dSteady-state factor VIII (FVIII) activity levels were estimated in 143 adults and adolescents using PK modeling.

Half-life image

What is half-life?

Half-life is the time it takes for the level of factor in the blood to fall by half.

Half-life image

What is half-life?

Half-life is the time it takes for the level of factor in the blood to fall by half.

Switch to fewer infusions.

Compared with standard half-life dosing schedules, the simple, fixed dosing routine of Esperoct® calls for fewer infusions per year.

Esperoct® infusion dosing in adults and adolescents
Esperoct® infusion dosing in adults and adolescents

No dose adjustment needed.

If you previously infused every other day

If you previously infused 3x/week

Rolled up jump rope
Esperoct® infusion dosing in children ages 0 to 12 years
Esperoct® infusion dosing in children ages 0 to 12 years

No dose adjustment needed.e

If your child previously infused every other day

If your child previously infused 3x/week

eInterval can be adjusted based on individual response to treatment.

castle with flags

The Medical and Scientific Advisory Council
The Medical and Scientific Advisory Council

A MASAC recommendation.

The Medical and Scientific Advisory Council (MASAC) recommends that prophylaxis factor be considered optimal therapy for people with severe hemophilia A.

Esperoct® use in daily life
Esperoct® use in daily life

Esperoct® goes where you go.

Recombinant factor VIII Esperoct® can be used in situations where bleeding may happen:

  • As a prophylaxis treatment for hemophilia A
  • Used on-demand for sudden bleeds
  • Used in and after surgery
Male and female Hemophilia Community Liaisons
Male and female Hemophilia Community Liaisons

HCL Connect.

Questions about switching to Esperoct®? Connect with your Hemophilia Community Liaison (HCL) for personalized support in your journey with hemophilia A. Find your HCL now.

Esperoct® FAQs
Esperoct® FAQs

Your questions, answered.

Question: What is a trough level?

Answer: Factor in the bloodstream rises and falls in patients treated prophylactically with factor. It is highest right after an infusion and lowest right before an infusion. The low level right before infusion is called the trough level. Many factor products aim to keep trough levels at 1%. In a study of adults and adolescents who were treated with Esperoct® for prophylaxis, researchers found that extended half-life Esperoct® keeps trough levels at or above 3% all of the time, and 5% approximately 90% of the time.b,c,d

Question: What is MASAC (Medical and Scientific Advisory Council), the group that recommends prophylaxis factor as the optimal therapy for hemophilia A?

Answer: This branch of the National Hemophilia Foundation (NHF) is a group of physicians, researchers, and other medical professionals—all with expertise in bleeding disorders and infectious diseases—who meet twice a year with consumers and representatives from the NHF. The group issues treatment and research guidelines for the bleeding disorder community. Medical schools, pharmacists, insurance companies and many others then use MASAC’s guidance in their decision making.

Selected Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face
What should I tell my healthcare provider before using Esperoct®?
  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®
What are the possible side effects of Esperoct®?
  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.